Cobicistat Oral Tablet

DRUG2 trials

Sponsors

German Cancer Research Center, Pyramid Biosciences

Conditions

Advanced Stage or Metastatic Pancreatic Ductal AdenocarcinomaCYP3A InhibitorDrug-drug InteractionPancreatic AdenocarcinomaPancreatic CancerPancreatic Neoplasm

Phase 1

A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma

TerminatedNCT05494866

German Cancer Research CenterAdvanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma, CYP3A Inhibitor, Pancreatic Adenocarcinoma +2

Start: 2022-12-07End: 2024-03-15Updated: 2025-03-25

A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers

CompletedNCT05692570

Pyramid BiosciencesDrug-drug Interaction

Start: 2022-09-09End: 2022-11-12Updated: 2023-01-20

Related Papers

Protocol of the <scp>IntenSify‐Trial</scp>: An open‐label phase I trial of the <scp>CYP3A</scp> inhibitor cobicistat and the cytostatics gemcitabine and nab‐paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy

Clinical and Translational Science2023-11-035 citations